Aliri has supported 5 of the 20 approved OGNs on market as they transitioned from preclinical to clinical to FDA approval Aliri is proud to be a trailblazer in the bioanalysis of RNAi therapeutics with significant experience supporting the development of oligonucleotides, which includes siRNAs, ASOs, PPMOs, ARCs/AOCs, and other RNAi conjugates.
Our tenured team of scientists are continuously innovating and adapting our methodologies for improved
assay sensitivity and specificity to deliver accurate and reliable data to our sponsors.
This has led to the critical application and optimization of available analytical approaches, including novel SPE and hybridization extraction techniques that can achieve subnanogram per milliter LLOQ’s with the
specificity of LC/MS detection.
Download the fact sheet to learn more.